|
| Press Releases |
|
 |
|
| Wednesday, May 27, 2015 |
|
|
Eisai Receives Positive CHMP Opinion on Indication Expansion for Antiepileptic Agent Fycompa (Perampanel) as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the use of Fycompa (perampanel) for the adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in adult and adolescent patients from 12 years of age with idiopathic generalized epilepsy. more info >> |
|
| Thursday, May 21, 2015 |
|
|
Eisai to Promote Clinical Trial Data Disclosure for The Advancement of Science and Medicine |
| Eisai Co., Ltd. has announced today that, in order to further promote transparency in clinical trial data disclosure, it has determined its policy on clinical trial data disclosure and is making clinical trial data publicly available to researchers via an external website (www.clinicalstudydatarequest.com). more info >> |
|
| Wednesday, May 20, 2015 |
|
|
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer in Japan |
| Eisai Co., Ltd. announced that it has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. more info >> |
|
| Thursday, May 14, 2015 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
more info >> |
|
| Monday, April 27, 2015 |
|
|
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. and Nihon Medi-Physics Co., Ltd. announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, April 13, 2015 |
|
|
Eisai and Genomics Plc to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development |
| Eisai Co., Ltd. and Genomics plc announced today that they have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. more info >> |
|
| Friday, April 3, 2015 |
|
|
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal |
| A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. more info >> |
|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
| Tuesday, March 3, 2015 |
|
|
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept |
| Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) has been accepted for review by the Jiangsu Food and Drug Administration in China. more info >> |
|
| Monday, March 2, 2015 |
|
|
Eisai Launches Anticancer Agent Lenvima in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Masverse Unveils Groundbreaking Blockchain Platform 
Apr 27, 2024 02:40 HKT/SGT
|
|
|
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans
Apr 26, 2024 23:00 HKT/SGT
|
|
|
Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family
Apr 26, 2024 22:25 HKT/SGT
|
|
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 26, 2024 21:10 HKT/SGT
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023
Apr 26, 2024 18:26 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 17:30 HKT/SGT
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
Edvantage Group Announces FY2024 Interim Results
Apr 26, 2024 13:43 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 13:27 HKT/SGT
|
|
|
Imexpharm Corporation Hosts Shareholders, Analysts and Potential Investors at its 2024 Annual General Meeting
Apr 26, 2024 13:16 HKT/SGT
|
|
|
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
|
|
|
Jeff Martin Auctioneers to Manage Sale of Sabine Mining Company Assets for North American Coal
Apr 26, 2024 08:00 HKT/SGT
|
|
|
Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase
Apr 25, 2024 21:00 HKT/SGT
|
|
|
Black Spade Donates Art and Jewellery Collection To Hong Kong Red Cross
Apr 25, 2024 20:40 HKT/SGT
|
|
|
Q2 Metals Announces Assay Results from Its 2023 Inaugural Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada
Apr 25, 2024 19:09 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
